Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance
about
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseasesSodium dependent multivitamin transporter (SMVT): a potential target for drug deliveryAge-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilersABCG2-dependent dye exclusion activity and clonal potential in epithelial cells continuously growing for 1 month from limbal explants.Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacinBinary and ternary combinations of anti-HIV protease inhibitors: effect on gene expression and functional activity of CYP3A4 and efflux transporters.Evaluation of initial and steady-state gatifloxacin pharmacokinetics and dose in pulmonary tuberculosis patients by using monte carlo simulations.A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.The Role of Eukaryotic and Prokaryotic ABC Transporter Family in Failure of Chemotherapy.Bitter melon extracts enhance the activity of chemotherapeutic agents through the modulation of multiple drug resistance.Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.Targeted lipid based drug conjugates: a novel strategy for drug delivery.Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.Amino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, LopinavirEffect of emergence of fluoroquinolone resistance on intrinsic expression of P-glycoprotein phenotype in corneal epithelial cells.Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.Bactericidal effect of S-nitrosothiols against clinical isolates from keratitis.Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.The dual-targeted HER1/HER2 tyrosine kinase inhibitor lapatinib strongly potentiates the cardiac myocyte-damaging effects of doxorubicin.
P2860
Q24601963-7654A56A-CF35-42DE-A325-41746068A364Q26863420-14A644DF-D68E-4D1D-B150-76F9575E7C34Q28533470-FB3B284D-8C3A-4D9D-BFDF-D17B063C1EC8Q33851021-70DA02F3-3188-4FF9-8266-0530DDEFD4FBQ35374935-8334AAFF-2532-4D10-B165-589B229F3008Q35531564-DC77973A-3DF6-4945-B7AC-F1890DE0B7E1Q37124090-552E9654-FBC0-47A9-8752-6790D6011332Q37204002-CAEB7885-683B-4A88-B7ED-2297D2FA5DEDQ37576360-EF90F50B-5675-46D8-BE55-2BB1ADE5438CQ37610933-0A664E2E-7053-4134-AB0D-0EB626761A5AQ37958069-174C7DFC-71E5-46D0-BBAD-3E1803232DFDQ39332407-5AD56BAD-3F6C-4FFE-B9B6-F716D9F8F87EQ39335333-B8DDCEDE-B0AB-4D08-8322-2484134ECD49Q39395865-A9880328-6193-43CD-BEC3-7F6947C97694Q39492357-A702405C-EF9A-4192-AA32-5BD81A46514BQ40500118-F20FC8FB-9FD6-4B9C-B7FE-22FA7F7E3B96Q42042537-4D13D7F7-EFC1-41C6-A1BB-CB1D1A861D82Q43168123-A72A2D0B-1340-4323-8EB9-E6453F584436Q44312601-59679E74-28BB-4E7D-9C12-6B53E8CDE287
P2860
Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@ast
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@en
type
label
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@ast
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@en
prefLabel
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@ast
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@en
P2093
P2860
P1476
Interaction of gatifloxacin wi ...... mechanism for drug resistance
@en
P2093
Ashim K Mitra
Aswani Dutt Vadlapudi
Deep Kwatra
Dhananjay Pal
Ramya Krishna Vadlapatla
P2860
P304
P356
10.1016/J.IJPHARM.2010.05.027
P407
P577
2010-05-24T00:00:00Z